CMS to work closely with FDA on accelerated approval payment reforms
The FDA has historically not dealt with drug pricing, unless it’s related to savings from generic drug competition.
But that’s slowly changing now, with CMS …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.